Massimo Gola
Florence, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.
Journal: Clinical and experimental dermatology
Published: April 12, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.
Journal: Dermatology and therapy
Published: March 11, 2026
T2-Reg: a regional web registry on Th2-mediated diseases.
Journal: Italian journal of dermatology and venereology
Published: January 12, 2026
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).
Journal: Acta dermato-venereologica
Published: November 16, 2025
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: November 07, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.
Journal: Dermatology and therapy
Published: August 12, 2025
Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 05, 2025
Upadacitinib dose adjustment in moderate-to-severe atopic dermatitis: insights from a multicenter real-world study.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: May 23, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: May 22, 2025
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 05, 2024
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study.
Journal: Clinical and experimental dermatology
Published: November 19, 2024
Last Updated: 09/26/2026